Cat. #151432
Anti-CR2 [BU33]
Cat. #: 151432
Sub-type: Primary antibody
Unit size: 100 ug
Availability: 10-12 weeks
Target: Complement component (3d/Epstein Barr virus) receptor 2 (CR2, CD21)
Class: Monoclonal
Application: FACS ; IHC ; IP ; WB
Reactivity: Human
Host: Mouse
£300.00
This fee is applicable only for non-profit organisations. If you are a for-profit organisation or a researcher working on commercially-sponsored academic research, you will need to contact our licensing team for a commercial use license.
Contributor
Institute: University of Birmingham
Tool Details
*FOR RESEARCH USE ONLY (for other uses, please contact the licensing team)
- Name: Anti-CR2 [BU33]
- Alternate name: Complement Component 3d Receptor 2; Epstein-Barr Virus Receptor 2; Complement C3d Receptor; EBV Receptor; C3DR; CD21 Antigen; CVID7; SLEB9; CD21; Cr2; CR
- Research fields: Cell signaling and signal transduction;Immunology
- Clone: BU33
- Tool sub type: Primary antibody
- Class: Monoclonal
- Purpose: Marker
- Conjugation: Unconjugated
- Strain: Balb/c
- Reactivity: Human
- Host: Mouse
- Application: FACS ; IHC ; IP ; WB
- Description: CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and ...
- Immunogen: HF B1 plasmactyoid cell line, considered to be "late B like"
- Isotype: IgG1
- Myeloma used: NS0
Target Details
- Target: Complement component (3d/Epstein Barr virus) receptor 2 (CR2, CD21)
- Tissue cell line specificity: Mouse
- Target background: CR2 is expressed strongly on mature B cells, follicular dentritic cells and weakly on immature thymocytes and T lymphocytes. In B-cell ontogeny, CR2 appears after the pre-B-stage, is maintained during peripheral B-cell development and is lost upon terminal differentiation into plasma cells. CR2 expression is also gradually lost after stimulation of B cells in vitro. CR2 functions as a receptor for C3d, C3dg and iC3b Complement components and for EBV and for IFN alpha. CR2 binds to CD23 and ...
Applications
- Application: FACS ; IHC ; IP ; WB
Handling
- Format: Liquid
- Concentration: 0.9-1.1 mg/ml
- Unit size: 100 ug
- Storage buffer: PBS with 0.02% azide
- Storage conditions: -15° C to -25° C
- Shipping conditions: Shipping at 4° C
References
- Mayall et al. 2001. J Comp Pathol. 124(1):83-7. PMID: 11428193.
- The anti-human CD21 antibody, BU33, identifies equine B cells.
- Scholssman SF. et al. 1995. Leucocyte Typing V. Oxford University Press. ISBN-13: 978-0192623768
- Henchoz et al. 1994. Immunology. 81(2):285-90. PMID: 7512529.
- Stimulation of human IgE production by a subset of anti-CD21 monoclonal antibodies: requirement of a co-signal to modulate epsilon transcripts.
- Bacon et al. 1993. Eur J Immunol. 23(10):2721-4. PMID: 76...
